重要内容提示： 本次会议是否有否决议案：无 证券代码：603205 证券简称：健尔康 公告编号：2025-027 健尔康医疗科技股份有限公司 2025年第一次临时股东会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、 会议召开和出席情况 (一)股东会召开的时间：2025 年 9 月 16 日 (二)股东会召开的地点：江苏省常州市金坛区直溪镇工业集中区健尔康路 1 号办 公楼一楼会议室 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 209 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 110,511,142 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 70.8404 | (四)表决方式是否符合《公司法》及《公司章程》的规定，股东会主持情况等。 本次会议采用现场与网络投票相结合的方式，对需审议议案进行逐项投票表决。 会议由公司董事长陈国平先生主持。会议召集、召 ...

上海市广发律师事务所 关于健尔康医疗科技股份有限公司 2025年第一次临时股东大会的法律意见书 致:健尔康医疗科技股份有限公司 健尔康医疗科技股份有限公司(以下简称"公司")2025年第一次临时股 东大会于 2025 年 9 月 16 日在江苏省常州市金坛区直溪镇工业集中区健尔康路 1 号办公楼一楼会议室召开。上海市广发律师事务所经公司聘请,委派占新越律师、 汤颖律师出席现场会议,根据《中华人民共和国公司法》(以下简称"《公司法》")、 《上市公司股东会规则》(以下简称"《股东会规则》")等法律法规、其他规 范性文件以及《健尔康医疗科技股份有限公司章程》(以下简称"《公司章程》") 的规定,就本次股东大会的召集和召开程序、召集人及出席会议人员的资格、会 议议案、表决方式和表决程序、表决结果和会议决议等出具本法律意见书。 为出具本法律意见书,本所律师对本次股东大会所涉及的有关事项进行了审 查,查阅了相关会议文件,并对有关问题进行了必要的核查和验证。 公司已向本所保证和承诺,公司向本所律师所提供的文件和所作的陈述和说 明是完整的、真实的和有效的,有关原件及其上面的签字和印章是真实的,且一 切足以影响本法律意见书的 ...

证券代码：603205 证券简称：健尔康 公告编号：2025-025 健尔康医疗科技股份有限公司 （一）审议通过《关于免去监事会主席职务的议案》 第二届监事会第九次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、 监事会会议召开情况 健尔康医疗科技股份有限公司（以下简称"公司"）第二届监事会第九次会 议于 2025 年 9 月 16 日以现场方式在公司会议室召开，会议通知于 2025 年 9 月 12 日以书面等方式送达。本次会议由监事会主席汤红芳女士主持，会议应到监 事 3 人，实到监事 3 人。本次监事会的召集、召开和表决程序符合《中华人民共 和国公司法》等有关法律法规及《健尔康医疗科技股份有限公司章程》的规定。 二、监事会会议审议情况 经全体监事审议，会议表决情况如下： 根据《中华人民共和国公司法》《关于新＜公司法＞配套制度规则实施相关 过渡期安排》《上市公司章程指引》等相关法律法规的规定，结合公司实际情况， 公司将不再设置监事会和监事，免去汤红芳女士监事会主席的职务。 表决结果：3 票同意，0 票反对 ...

Core Viewpoint - The company Jianerkang experienced a slight decline in stock price on September 10, with a trading volume of 31.35 million yuan, indicating a potential concern in market sentiment [1] Financing Summary - On September 10, Jianerkang had a financing buy-in amount of 2.70 million yuan, with a net financing purchase of 1.09 million yuan after repayments [1][2] - The total financing balance as of September 10 was 88.67 million yuan, accounting for 7.66% of the company's market capitalization [2] - The company had no short selling activity on the same day, with a remaining short position of 100 shares valued at 2,969 yuan [2] Company Profile - Jianerkang Medical Technology Co., Ltd. is located in Jiangsu Province, established on June 6, 2000, and is set to be listed on November 7, 2024 [2] - The company's main business includes the research, production, and sales of medical dressings and disposable medical devices, with revenue contributions from various product categories: nursing products (33.19%), surgical consumables (30.64%), polymer and auxiliary products (18.46%), disinfecting and cleaning products (16.93%), and others (0.79%) [2] Financial Performance - For the first half of 2025, Jianerkang reported a revenue of 466 million yuan, reflecting a year-on-year decrease of 7.60% [2] - The net profit attributable to the parent company was 48.15 million yuan, down 21.00% compared to the previous year [2] Dividend Information - Since its A-share listing, Jianerkang has distributed a total of 42.12 million yuan in dividends [3]

Group 1 - The core point of the news is that Jianerkang experienced a decline in stock price and trading volume, with a notable net financing outflow on September 3, 2023 [1] - On September 3, Jianerkang's stock price fell by 3.00%, with a trading volume of 71.09 million yuan, and a net financing outflow of 1.82 million yuan [1] - As of September 3, the total balance of margin trading for Jianerkang was 91.96 million yuan, with financing accounting for 8.02% of the circulating market value [1] Group 2 - As of June 30, Jianerkang had 18,200 shareholders, a decrease of 0.22% from the previous period, while the average circulating shares per person increased by 0.22% to 1,650 shares [2] - For the first half of 2025, Jianerkang reported operating revenue of 466 million yuan, a year-on-year decrease of 7.60%, and a net profit attributable to shareholders of 48.15 million yuan, down 21.00% year-on-year [2] Group 3 - Jianerkang has distributed a total of 42.12 million yuan in dividends since its A-share listing [3]

Group 1 - The core viewpoint of the news is that Jianerkang experienced a decline in stock price and trading volume, with significant financing activities reported on September 2 [1] - On September 2, Jianerkang's stock fell by 2.13%, with a trading volume of 86.31 million yuan, and a net financing purchase of 2.67 million yuan [1] - As of September 2, the total balance of margin trading for Jianerkang was 93.78 million yuan, accounting for 7.93% of its market capitalization [1] Group 2 - As of June 30, Jianerkang had 18,200 shareholders, a decrease of 0.22% from the previous period, with an average of 1,650 circulating shares per shareholder, an increase of 0.22% [2] - For the first half of 2025, Jianerkang reported a revenue of 466 million yuan, a year-on-year decrease of 7.60%, and a net profit attributable to shareholders of 48.15 million yuan, down 21.00% year-on-year [2] Group 3 - Jianerkang has distributed a total of 42.12 million yuan in dividends since its A-share listing [3]

Core Viewpoint - The company is planning to change its registered capital, abolish the supervisory board, and amend its Articles of Association in preparation for the 2025 first extraordinary general meeting of shareholders [2][5]. Group 1: Meeting Regulations - The board of directors is responsible for ensuring the protection of shareholders' legal rights and maintaining the order and efficiency of the meeting [2]. - Shareholders attending the meeting have the right to speak and vote, and must not disrupt the meeting's normal order [2][3]. - Voting will be conducted through a combination of on-site and online methods, with shareholders required to choose one method [3]. Group 2: Agenda and Proposals - The meeting will review two proposals, and there is no need for separate voting for small and medium investors [3]. - The first proposal involves changing the registered capital and abolishing the supervisory board, along with amending the Articles of Association [5]. - The company plans to distribute a cash dividend of 0.351 yuan per share and increase the share capital by 0.3 shares per share from capital reserves, changing the total share capital from 120 million shares to 156 million shares [5][8]. Group 3: Amendments to Governance - The supervisory board will be abolished, and its powers will be transferred to the audit committee of the board of directors [5]. - The amendments to the Articles of Association will comply with the latest regulations and reflect the company's operational realities [6]. - The company will no longer have a supervisory board, and the current supervisors will be relieved of their duties upon the approval of the proposal [5][6].

健尔康医疗科技股份有限公司 2025 年第一次临时股东大会 会议资料 二〇二五年九月 目 录 2025 年 第 一 次 临 时 股 东 大 会 会 议 程........................................3 2025 年 第 一 次 临 时 股 东 大 会 会 议 须 知....................................4 关于变更公司注册资本、取消监事会并修订《公司章程》及 其 附 件 的 议 案.............................................................................5 关 于 修 订 和 制 定 部 分 治 理 制 度 的 议 案.................................154 2025 年第一次临时股东大会会议须知 各位股东及股东代表： 为了维护投资者的合法权益，确保股东在本公司 2025 年第一次临时股东 大会期间依法行使权利，保证股东大会的正常秩序和议事效率，依据中国 证券监督管理委员会《上市公司股东会规则》等有关规定，制定如下有关规 定： 一 ...

Core Insights - The company Jianerkang (603205) reported a decline in total revenue and net profit for the first half of 2025, with total revenue at 466 million yuan, down 7.6% year-on-year, and net profit at 48.15 million yuan, down 21.0% [1][3] - The second quarter showed a more significant decline, with total revenue of 225 million yuan, down 23.01% year-on-year, and net profit of 19.34 million yuan, down 46.25% [1] - The company's accounts receivable is notably high, with accounts receivable accounting for 162.43% of the latest annual net profit [1][3] Financial Performance - Total revenue for 2024 was 505 million yuan, compared to 466 million yuan in 2025, reflecting a decrease of 7.6% [1] - Net profit decreased from 60.94 million yuan in 2024 to 48.15 million yuan in 2025, a decline of 21.0% [1] - The gross margin improved to 24.16%, up 6.91% year-on-year, while the net margin decreased to 10.33%, down 14.5% [1] - Total expenses (selling, administrative, and financial) amounted to 30.82 million yuan, representing 6.61% of revenue, an increase of 62.69% year-on-year [1] - Earnings per share fell from 0.52 yuan in 2024 to 0.31 yuan in 2025, a decrease of 40.38% [1] Cash Flow and Debt - The company reported cash assets of 743 million yuan, a significant increase of 151.52% from the previous year [1] - Accounts receivable slightly decreased from 200 million yuan to 195 million yuan, a decline of 2.25% [1] - The company has interest-bearing debt of 3.77 million yuan, indicating a manageable level of debt [1] Return on Investment - The company's Return on Invested Capital (ROIC) for the previous year was 9.73%, which is considered average [3] - Historical data shows a median ROIC of 21.46% since the company went public, indicating strong investment returns in the past [3] - The net profit margin for the previous year was 11.5%, suggesting average added value from products or services [3]

Meeting Overview - The second board meeting of Jianerkang Medical Technology Co., Ltd. was held on August 28, 2025, with all 9 directors present, complying with relevant laws and regulations [1][2]. Resolutions Passed - The board approved the full and summary reports for the 2025 semi-annual report, with a unanimous vote of 9 in favor [2]. - The board also approved the special report on the storage and use of raised funds for the first half of 2025, again with a unanimous vote of 9 in favor [2]. - A resolution was passed to change the company's registered capital, abolish the supervisory board, and amend the company's articles of association, with a unanimous vote of 9 in favor. This change aligns with the new Company Law effective from July 1, 2024 [3][4]. - The board approved the revision and formulation of several governance systems to enhance operational standards and governance structure, with a unanimous vote of 9 in favor [4]. - A proposal to convene the first extraordinary general meeting of shareholders in 2025 was also approved, with a unanimous vote of 9 in favor [5].